Finvest
THC Healthcare Services · Hospitals · Surgery centers · Buybacks · Thesis updated July 12, 2026

Surgery centers drive Tenet higher

01 Running thesis

Execution is winning, law risk waits

Tenet is doing what investors wanted: grow the higher-margin USPI surgery-center business, keep hospitals steady, and use cash for buybacks. Q1 2026 supported that story. Adjusted diluted EPS was $4.82, above the roughly $4.20 consensus view, and management reaffirmed full-year 2026 adjusted EBITDA guidance of $4.485 billion to $4.785 billion.

The mix shift matters. Ambulatory Care revenue grew 10.6% year over year in Q1 2026, much faster than Hospital Operations revenue growth of 0.5%. Tenet is adding surgery centers through acquisitions, new centers, and more complex procedures that can move out of hospitals.

Capital returns are also part of the thesis. Tenet repurchased $318 million of stock in Q1 2026 and had $1.172 billion still authorized at March 31, 2026. The Conifer transaction adds another possible funding source, with $1.9 billion due to Tenet over three years.

The bear case has not gone away. Tenet has not yet given a clear dollar estimate for the 2027 impact of OBBBA on Medicaid coverage, reimbursement, patient volumes, or unpaid care. That is why the stock can look operationally strong while still carrying a policy risk that is hard to price.

Apr 2026Q1 2026 results strengthened the operating story. Tenet beat EPS expectations, reaffirmed full-year adjusted EBITDA guidance, repurchased $318 million of stock, and reported 10.6% Ambulatory Care revenue growth.
Feb 2026The 2025 Form 10-K added the Conifer simplification to the thesis. Tenet returned to full ownership of Conifer and secured a $1.9 billion payment stream over three years.
Oct 2025Q3 2025 showed strong execution in both segments, and management raised full-year adjusted EBITDA guidance. USPI continued to grow, while buybacks stayed active.
Jul 2025The Q2 2025 filing introduced OBBBA as a major long-term policy risk. Tenet said the law is expected to materially affect Medicaid funding and enrollment, with key provisions starting in 2027.
Jul 2025Q2 2025 earnings were well ahead of expectations, and Tenet raised its full-year adjusted EBITDA outlook. The board also authorized a $1.5 billion increase to the buyback program.
Apr 2025Q1 2025 confirmed the ambulatory pivot, with Ambulatory Care revenue up 20.0% year over year. Tenet also repurchased $348 million of stock during the quarter.
02 Business model

Hospitals fund the outpatient pivot

Tenet makes money by providing care and getting paid by commercial insurers, Medicare, Medicaid, and patients. Its two main pieces are Hospital Operations and Services, plus Ambulatory Care through USPI.

The hospital business is large and important, but it grows more slowly and faces more pressure from labor costs, payer contracts, regulation, and unpaid care. In Q1 2026, Hospital Operations revenue was $4.048 billion, up 0.5% year over year, with same-hospital admissions up 0.2%.

USPI is the growth engine. It runs ambulatory surgery centers and surgical hospitals, where patients can get procedures without a full hospital stay. In Q1 2026, Ambulatory Care revenue was $1.320 billion, up 10.6% year over year.

Conifer handles revenue cycle work, which means billing, collections, and payment administration. Tenet returned to full ownership of Conifer effective January 1, 2026, and management now says AI and automation are helping productivity there and in hospital administration. The open question is how much of those savings will show up in margins.

03 Product portfolio

Care sites and payment pipes

Growth engine

USPI ambulatory surgery centers

USPI operates 520 ambulatory surgery centers. These centers focus on outpatient procedures, including orthopedics, gastroenterology, and urology.

Growth engine

USPI surgical hospitals

Tenet also owns 24 surgical hospitals through USPI. These facilities support higher-acuity procedures that can still be done outside a traditional hospital setting.

Cash cow

Acute care hospitals

Tenet operates 49 hospitals that provide inpatient care, emergency care, surgeries, and specialty services. This is the biggest revenue base, but it is more exposed to labor costs and reimbursement policy.

Steady

Physicians and outpatient support sites

The hospital segment includes employed physicians, imaging centers, urgent care, and other outpatient locations. These sites help feed patient volume into Tenet's broader care network.

Option

Conifer revenue cycle services

Conifer helps manage billing and collections. Full ownership gives Tenet more control, and AI-driven automation may improve productivity, but the savings are not yet fully quantified.

04 Business segments

Q1 mix still leans hospital

Hospital Operations and Services75%flat
Ambulatory Care25%growing fast

Segment mix uses Q1 2026 net operating revenue: Hospital Operations and Services at $4.048 billion and Ambulatory Care at $1.320 billion. Hospitals are still most of revenue, while USPI is the faster-growing piece.

05 Risk factors

What could break the plan

OBBBA Medicaid shock

High impact · Medium odds

Tenet says OBBBA is expected to materially affect Medicaid funding and enrollment, with major healthcare provisions starting in 2027. If more patients lose coverage or Medicaid payments fall, hospitals could see lower revenue and more unpaid care. The risk is large because Tenet has not yet put a dollar range on it.

We watchWatch management comments on 2027 Medicaid exposure, uncompensated care, and any OBBBA impact range.

Hospital margin pressure

High impact · Medium odds

The hospital segment is still the largest revenue source. It can be hurt by nurse and doctor shortages, wage inflation, weak payer mix, and tough managed care renewals. Q1 2026 revenue growth was only 0.5%, so there is not much room for a cost spike.

We watchWatch same-hospital admissions, payer mix, wage expense, and hospital adjusted EBITDA margin.

USPI acquisition discipline

Medium impact · Medium odds

Tenet is using acquisitions to grow ambulatory surgery centers. That can work well if prices are fair and new centers ramp as planned. It can hurt returns if Tenet overpays for ASCs or buys centers with weaker procedure volume.

We watchWatch ASC acquisition multiples, de novo center openings, same-facility case growth, and net revenue per case.

Capital allocation misstep

Medium impact · Medium odds

Tenet has several good uses for cash: debt paydown, USPI deals, hospital investment, and buybacks. The Conifer agreement adds $1.9 billion over three years, while the buyback authorization had $1.172 billion left at March 31, 2026. Returns could suffer if cash goes to expensive deals or buybacks at a poor price.

We watchWatch how Tenet splits Conifer proceeds among debt reduction, USPI M&A, capital spending, and repurchases.

AI and automation risk

Medium impact · Low odds

Management says AI and automation are improving productivity, especially in Conifer and administrative work. Tenet also names AI as a risk factor, which means errors, privacy issues, bad outputs, or system failures could create legal and operating problems. The upside is real, but investors still need measurable proof.

We watchWatch quantified cost savings, billing accuracy, cyber events, and any new AI-related legal or compliance disclosures.
06 Quick answers

In one breath

What does Tenet Healthcare do?

Tenet runs hospitals and outpatient surgery centers. Its USPI business operates ambulatory surgery centers, while its hospital segment provides emergency care, inpatient care, outpatient care, and surgeries.

Why is USPI important to Tenet?

USPI is Tenet's faster-growing ambulatory care business. In Q1 2026, Ambulatory Care revenue grew 10.6% year over year, compared with 0.5% growth in Hospital Operations.

What is the biggest risk for Tenet stock?

The biggest long-term risk is OBBBA, because Tenet says it is expected to materially affect Medicaid funding and enrollment starting in 2027. The company has not yet given a clear dollar estimate of the impact.

Is Tenet returning cash to shareholders?

Yes. Tenet repurchased $318 million of stock in Q1 2026 and had $1.172 billion left under its repurchase program at March 31, 2026.